Have you ever heard of the merger between IMS Health and Quintiles? If not, then it’s time to tune in because this was one of the most significant collaborations in healthcare history. Back in 2016, two giants in the industry joined forces to create a powerhouse team dedicated to revolutionizing the way healthcare operates. It’s been over four years since the IMS Health-Quintiles merger, and the impact of this partnership is still being felt in the industry today.
IMS Health was already a dominant player in healthcare when it decided to merge with Quintiles in 2016. The former was a leading provider of market research and analytics services while the latter was a world-renowned clinical research company. Together, the two organizations combined their wealth of expertise and resources to create a new entity called IQVIA. This merger was a game-changer for the healthcare industry, and the impact of the collaboration can be seen in the way healthcare organizations operate today.
IQVIA has quickly become a go-to source for healthcare solutions. With a focus on data-driven insights and innovative technologies, IQVIA provides clients with unparalleled expertise in clinical, commercial, and real-world insights. Underlying the success of IQVIA is its mission to make a positive impact on human health. The IMS Health-Quintiles merger laid the foundation for this important mission, and the legacy of this partnership is something that the healthcare industry will continue to benefit from for years to come.
IMS Health and Quintiles Merge
IMS Health and Quintiles, two prominent players in the healthcare industry, announced their merger in October 2016. This merger created a new entity, IQVIA, that aimed to revolutionize the way healthcare analytics and insights are delivered.
The merger was seen as a strategic move for both companies. IMS Health was known for its vast data offerings, while Quintiles was an expert in clinical trial management. Combining their strengths would allow the new entity to offer end-to-end solutions for the healthcare industry, from clinical trial management to commercialization.
Benefits of the Merger
- The merger created a comprehensive suite of solutions that would help healthcare companies streamline their operations.
- IQVIA now has access to a vast pool of healthcare data that would allow it to provide more accurate and detailed insights to its clients.
- The merger allowed IQVIA to deliver a more complete set of services, from clinical trial management to commercialization, to healthcare companies.
The Birth of IQVIA
With the merger complete, IQVIA was born. The company operated in over 100 countries and had a workforce of more than 50,000 employees. The company’s main focus was to provide healthcare companies with a comprehensive suite of solutions that would allow them to make more informed decisions.
The company’s offerings included:
- Real-world insights: Data and analytics that would help healthcare companies understand market dynamics and drive product development.
- Clinical solutions: Management of clinical trials and development of new treatments.
- Clinical operations: The planning and implementation of clinical trials.
- Commercialization: Services that would help healthcare companies bring their products to market.
Conclusion
The merger of IMS Health and Quintiles created IQVIA, a new player in the healthcare industry that aimed to provide comprehensive solutions to healthcare companies. With access to vast amounts of data and a wide range of services, the new entity was expected to bring about significant changes in the healthcare analytics and insights space.
| Company | IMS Health | Quintiles | IQVIA |
|---|---|---|---|
| Founded | 1954 | 1982 | 2016 (after merger) |
| Headquarters | Danbury, Connecticut | Durham, North Carolina | Danbury, Connecticut |
| Key figures | Ari Bousbib (CEO) | Tom Pike (CEO) | Ari Bousbib (CEO) |
The table provides basic information about the companies involved in the merger.
Merging of Two Industry Giants
IMS Health and Quintiles merged in 2016, forming a behemoth of a company in the healthcare industry. The move brought together two of the biggest players in the field of healthcare data and consulting. The merger was valued at around $17.6 billion, making it one of the largest healthcare mergers in history.
- The merger was a response to the changing landscape of the healthcare industry. With the increasing importance of data and analytics, it made sense for these two companies to come together and combine their strengths.
- The new entity, known as Quintiles IMS Holdings, has a massive footprint in the healthcare industry, with operations in more than 100 countries. Its expertise spans the entire healthcare value chain, from clinical trials to commercialization and post-market surveillance.
- The merger has allowed Quintiles IMS Holdings to offer a broader range of services and solutions to its clients. Its offerings include everything from analytics and consulting to technology solutions and contract research services.
Quintiles IMS Holdings is now one of the most influential players in the healthcare industry. Its size and expertise make it a force to be reckoned with, and it is expected to continue to be a major player in the industry for years to come.
How the Merger Has Impacted the Industry
Since the merger, Quintiles IMS Holdings has been at the forefront of many of the biggest trends and developments in the healthcare industry. Its size and influence have allowed it to shape the direction of the industry in many ways.
One of the biggest impacts of the merger has been the way it has allowed Quintiles IMS Holdings to leverage data and analytics to drive innovation and improve patient outcomes. The company has invested heavily in advanced analytics capabilities, including artificial intelligence and machine learning, to provide its clients with insights that are more accurate and actionable than ever before.
| Impact of the Merger | Details |
|---|---|
| Increased Access to Data | The merger has given Quintiles IMS Holdings access to a massive amount of patient data, which it can use to inform its research and analytics. This data has been instrumental in driving innovation and improving patient outcomes. |
| Greater Scale and Reach | The merger has allowed Quintiles IMS Holdings to reach more patients in more countries than ever before. Its scale and reach have made it a leader in the healthcare industry and positioned it to be a major force in the future. |
| Accelerated Innovation | The combination of IMS Health and Quintiles has resulted in a more innovative and agile company, with a focus on developing new solutions and services that address the challenges faced by the healthcare industry. |
Overall, the merger of IMS Health and Quintiles has had a significant impact on the healthcare industry, driving innovation, improving patient outcomes, and positioning Quintiles IMS Holdings as a major player in the years to come.
Historical Timeline of IMS Health and Quintiles Merger
IMS Health, founded in 1954, is a leading global provider of information, technology, and services to the healthcare industry. The company provides innovative solutions to pharmaceutical and healthcare companies and has operations in more than 100 countries. Quintiles, founded in 1982, is a leading provider of biopharmaceutical development and commercial outsourcing services.
- May 2016: IMS Health and Quintiles announced they would merge to form QuintilesIMS, a leading healthcare solutions provider.
- October 2016: The merger was completed, and QuintilesIMS began trading on the NYSE under the symbol Q
- November 2017: QuintilesIMS rebranded as IQVIA – a combination of “IQ” representing the company’s focus on intelligence and “VIA” symbolizing the company’s role as a force for positive change in the industry.
The merger created a company with a broad range of capabilities to deliver end-to-end solutions to the biopharmaceutical marketplace. The combination of IMS Health’s data and technology expertise along with Quintiles’ clinical and commercial leadership is expected to drive innovation, increase efficiency, and accelerate commercial success for clients.
The companies’ combined resources and expertise enable IQVIA to offer comprehensive solutions that span the entire life cycle of a drug. The table below highlights the key areas of focus for IQVIA in the development and commercialization of innovative therapies.
| Key areas of focus for IQVIA | Examples of Solutions |
|---|---|
| Clinical Development | Clinical trials, patient recruitment, real-world evidence, safety and risk management, medical writing and communications |
| Commercialization | Market access and analytics, sales and marketing support, patient engagement and adherence, channel optimization |
| Real-World Insights | Healthcare data analytics, research and consulting services, technology solutions, data management and integration |
The merger between IMS Health and Quintiles has created a powerhouse in the healthcare industry, empowering clients to develop and commercialize innovative therapies that improve patient outcomes. With a shared mission to drive healthcare forward, IQVIA is poised to transform the industry and deliver value to clients, patients, and stakeholders.
Advantages and Disadvantages of the Merger
The merger of IMS Health and Quintiles in 2016 created the world’s largest provider of healthcare insights, information, and technology services. While the merger provided a number of advantages, there were also some disadvantages that the new company had to consider.
- Advantages
- The merger created a global platform with enhanced scale, expertise, and capabilities in healthcare information and technology.
- IMS Quintiles can now offer end-to-end solutions throughout the entire drug development lifecycle, from early phase development to commercialization and beyond.
- The new company has a broader geographic and therapeutic reach, which has expanded its ability to serve its clients in emerging markets and new disease areas.
- The merger resulted in cost savings of approximately $100 million, which can be reinvested in research and development to develop new products and services.
The above advantages have positioned IMS Quintiles to be a global leader in the provision of healthcare insights, information, and technology services. However, the company has had to grapple with certain disadvantages, some of which are listed below.
- Disadvantages
- IMS Quintiles is now a larger organization, which means that decision-making may take longer and there is a greater risk of bureaucracy.
- There may be some duplication of resources and jobs, which could lead to layoffs or a reduction in force.
- The integration of two organizations with different cultures and values can be challenging.
To mitigate these disadvantages, IMS Quintiles has had to take a number of steps including streamlining its decision-making processes, retraining employees, and ensuring that it has a strong culture that is aligned with its values and mission.
| Advantages | Disadvantages |
|---|---|
| Global platform with enhanced scale, expertise, and capabilities in healthcare information and technology | Decision-making may take longer |
| End-to-end solutions throughout the entire drug development lifecycle | Duplication of resources and jobs can lead to layoffs |
| Expanded geographic and therapeutic reach | Integration of two organizations with different cultures and values can be challenging |
| Cost savings of approximately $100 million |
Overall, the merger has provided many advantages for IMS Quintiles, but also comes with some disadvantages. The company is already taking steps to address these and ensure that it remains a world leader in the provision of healthcare insights, information, and technology services.
Post-Merger Successes for IMS Health and Quintiles
Since the merger of IMS Health and Quintiles in 2016, the newly formed company, now known as IQVIA, has seen a number of successes. Here are some of the highlights:
- IQVIA has become the largest provider of contract research organization (CRO) services in the world, with a market share of around 12%. This has allowed them to continue to grow and expand their offerings, providing more value to clients and increasing their profitability.
- The merger has also allowed IQVIA to provide more comprehensive information and analytics services to their clients, thanks to the combination of IMS Health’s data capabilities and Quintiles’ research expertise. This has resulted in more accurate data insights and better decision-making for IQVIA’s clients.
- IQVIA has been able to leverage its newly combined resources to win larger contracts, including a $1.2 billion contract with the US Department of Veterans Affairs to manage the VA’s drug benefits program. This has helped the company establish itself as a major player in healthcare consulting and outsourcing.
In addition to these accomplishments, IQVIA has also made significant progress in improving patient outcomes and advancing clinical research:
IQVIA has been involved in a number of initiatives aimed at improving patient outcomes and advancing the field of clinical research. For example, the company has developed a platform called “Trialsphere”, which provides a secure environment for clinical trial data sharing and collaboration. This has allowed researchers to share data and insights more easily, leading to more efficient and effective clinical trials.
The company has also launched initiatives to improve access to healthcare in developing countries, such as the “Africa Healthcare Access Partnership” and the “Access to Medicines Index”. These initiatives aim to improve healthcare infrastructure in developing countries and increase access to life-saving medicines.
| Initiative | Description |
|---|---|
| Africa Healthcare Access Partnership | A partnership between IQVIA and the Bill & Melinda Gates Foundation, aimed at improving access to healthcare in Africa by building sustainable healthcare infrastructure and improving health systems. |
| Access to Medicines Index | An independent, publicly available tool that assesses how well pharmaceutical companies are doing in terms of providing access to medicines in developing countries. IQVIA provides technical support for the index. |
Overall, the merger between IMS Health and Quintiles has been a success, allowing IQVIA to become a major force in the healthcare industry. Through their various initiatives, the company has demonstrated a commitment to improving patient outcomes and advancing the field of healthcare research.
Integration of IMS Health and Quintiles Products and Services
When IMS Health and Quintiles merged in 2016, it was a strategic move aimed at expanding their product and service offerings. The combination of IMS Health’s healthcare data and analytics with Quintiles’ clinical research and consulting expertise has created a one-stop-shop for healthcare companies looking to improve outcomes and efficiencies.
The integration of IMS Health and Quintiles products and services has resulted in several key advancements:
- Enhanced clinical trial design capabilities – with access to IMS Health’s real-world evidence, Quintiles now has even greater insights into patient populations, enabling them to design more effective clinical trials.
- Improved patient recruitment – the combined knowledge of IMS Health and Quintiles allows for more targeted patient recruitment efforts, leading to better enrollment and retention rates.
- Increased post-market surveillance – with access to IMS Health’s vast healthcare data, Quintiles is able to better monitor drug safety and identify potential issues earlier.
Additionally, the merger has allowed the companies to offer a broader range of services to their clients, including:
- Healthcare consulting – the combined expertise of IMS Health and Quintiles allows for more comprehensive consulting services, from market research to regulatory compliance.
- Technology solutions – with IMS Health’s strong technology background and Quintiles’ clinical expertise, the companies can now offer end-to-end technology solutions for healthcare clients.
- Data analytics – with access to IMS Health’s vast healthcare data, Quintiles is able to provide more robust and accurate data analytics services.
The integration of IMS Health and Quintiles products and services has resulted in a more comprehensive offering for healthcare companies looking to improve outcomes and efficiencies. The combination of healthcare data and analytics with clinical research and consulting expertise has created a true powerhouse in the healthcare industry.
| IMS Health Products and Services | Quintiles Products and Services |
|---|---|
| Real-world patient data and analytics | Clinical research and development services |
| Pharmaceutical market intelligence | Consulting services |
| Technology solutions | Patient recruitment services |
| Prescription and sales data | Regulatory and compliance services |
The integration of IMS Health and Quintiles products and services has created a comprehensive offering that is unmatched in the healthcare industry. With a focus on improving outcomes and efficiencies, the companies are well-positioned for continued growth and success.
Impact of IMS Health and Quintiles Merger on the Healthcare Industry
The merger of IMS Health and Quintiles in 2016 was a major event in the healthcare industry, and it has since had a significant impact on the industry. Here are some of the ways this merger has affected the healthcare industry:
- The merger has created a larger and more powerful company with more resources available for research and development, which has led to increased efficiency and more innovative solutions.
- The new company has a more comprehensive database of healthcare information, which can be used to improve healthcare services and provide more personalized care to patients.
- The merger has resulted in more comprehensive healthcare analytics, which can help healthcare professionals make better decisions regarding patient care and optimize resource utilization.
The merger has also had significant implications for the pharmaceutical industry. Here are some of the ways the merger has affected the industry:
The merger has led to greater collaboration between pharmaceutical companies and healthcare providers, which has enabled the development of more effective therapies. The larger company can also leverage their enormous databases to conduct clinical trials and bring new treatments to market more efficiently.
Another important factor is that IMS Health and Quintiles were both leaders in the healthcare technology space. After the merger, they combined their technology offering making it extremely significant. The company is now in a position to offer a range of technology solutions that integrate healthcare data to provide actionable insights for clients.
| Impact | Description |
|---|---|
| Global Reach | The merger has enabled both companies to access new geographies, expanding their reach, and increasing their global footprint on healthcare. |
| Improved Efficiency | The merger has reduced operational redundancies, allowing for faster and more effective decision-making, resulting in improved efficiency. |
| Cost Savings | As with most mergers, the IMS Health and Quintiles merger led to some cost-saving opportunities through shared resources, resulting in savings for the company and lower costs for clients. |
The merger has had its challenges with the integration of two massive organizations and the consolidation of operations. However, as the company completes the integration phase, it is clear that the merger has had a positive impact on the industry and promises new innovations in the healthcare industry.
When did IMS Health and Quintiles Merge?
Q: When was the merger between IMS Health and Quintiles announced?
A: The agreement to merge between IMS Health and Quintiles was announced on May 3, 2016.
Q: When did the merger become official?
A: The merger between IMS Health and Quintiles became official on October 3, 2016.
Q: What is the new company called?
A: The new merged company is called Quintiles IMS Holdings, Inc.
Q: What was the purpose of the merger?
A: The primary purpose of the merger was to create a new global leader in healthcare information and technology solutions.
Q: How big is the new company?
A: The new company generated approximately $8.2 billion in revenue in 2016, and has over 50,000 employees in more than 100 countries.
Q: Who is leading the new company?
A: The new company is led by Ari Bousbib, who serves as Chairman and CEO of Quintiles IMS Holdings, Inc.
Q: What does the future hold for the new company?
A: The new company is poised to continue to grow and innovate in the healthcare space, and is expected to play a major role in shaping the future of healthcare delivery and outcomes.
Closing Thoughts
Thanks for taking the time to read about the merger between IMS Health and Quintiles. This historic merger created an innovative and dynamic company that is poised to lead the way in healthcare information and technology solutions. Please check back later for more updates on the future of healthcare and technology.